Colin J Sutherland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7943570/publications.pdf

Version: 2024-02-01

208 papers	11,569 citations	23500 58 h-index	39575 94 g-index
221 all docs	221 docs citations	221 times ranked	7802 citing authors

#	Article	IF	Citations
1	Deletions of the Plasmodium falciparum histidine-rich protein 2/3 genes are common in field isolates from north-eastern Tanzania. Scientific Reports, 2022, 12, 5802.	1.6	9
2	The primate malaria parasites Plasmodium malariae, Plasmodium brasilianum and Plasmodium ovale spp.: genomic insights into distribution, dispersal and host transitions. Malaria Journal, 2022, 21, 138.	0.8	10
3	Artemisinin susceptibility in the malaria parasite Plasmodium falciparum: propellers, adaptor proteins and the need for cellular healing. FEMS Microbiology Reviews, 2021, 45, .	3.9	24
4	The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957. Scientific Reports, 2021, 11, 1888.	1.6	10
5	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	0.9	97
6	The Role of Ultrasensitive Molecular Methods for Detecting Malariaâ€"The Broader Perspective. Clinical Infectious Diseases, 2021, 73, e1387-e1390.	2.9	10
7	Antimalarial drug resistance markers in human immunodeficiency virus (HIV)-positive and HIV-negative adults with asymptomatic malaria infections in Port Harcourt, Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 531-537.	0.7	3
8	Distinctive genetic structure and selection patterns in Plasmodium vivax from South Asia and East Africa. Nature Communications, 2021, 12, 3160.	5.8	32
9	Failure of rapid diagnostic tests in Plasmodium falciparum malaria cases among travelers to the UK and Ireland: Identification and characterisation of the parasites. International Journal of Infectious Diseases, 2021, 108, 137-144.	1.5	12
10	Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. Antimicrobial Agents and Chemotherapy, 2021, 65, e0087321.	1.4	7
11	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	0.9	51
12	A genetic intervention. ELife, 2021, 10, .	2.8	1
13	Subpatent Plasmodium with mutant pfmdr1, pfcrt, and pvmdr1 alleles from endemic provinces in Mindanao, the Philippines: implications for local malaria elimination. International Journal of Infectious Diseases, 2021, 110, 45-53.	1.5	3
14	Ex vivo susceptibility to new antimalarial agents differs among human-infecting Plasmodium species. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 5-11.	1.4	5
15	Plasmodium knowlesi detection methods for human infectionsâ€"Diagnosis and surveillance. Advances in Parasitology, 2021, 113, 77-130.	1.4	7
16	The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A systematic review and a pooled multicentre individual-patient meta-analysis. PLoS Medicine, 2020, 17, e1003359.	3.9	50
17	Selective whole genome amplification of Plasmodium malariae DNA from clinical samples reveals insights into population structure. Scientific Reports, 2020, 10, 10832.	1.6	19
18	Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet, The, 2020, 396, 1829-1840.	6.3	128

#	Article	IF	Citations
19	Mammalian malaria: Remembering the Alamo. Virulence, 2020, 11, 945-946.	1.8	0
20	The Plasmodium falciparum Artemisinin Susceptibility-Associated AP-2 Adaptin Î¼ Subunit is Clathrin Independent and Essential for Schizont Maturation. MBio, 2020, 11, .	1.8	27
21	Novel Endochin-Like Quinolones Exhibit Potent In Vitro Activity against Plasmodium knowlesi but Do Not Synergize with Proguanil. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	12
22	Recurrence of Plasmodium malariae and P. falciparum Following Treatment of Uncomplicated Malaria in North Sumatera With Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine. Open Forum Infectious Diseases, 2020, 7, ofaa116.	0.4	16
23	Plasmodium falciparum Isolates Carrying pf k13 Polymorphisms Harbor the SVMNT Allele of pfcrt in Northwestern Indonesia. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
24	A novel multiplex qPCR assay for detection of Plasmodium falciparum with histidine-rich protein 2 and 3 (pfhrp2 and pfhrp3) deletions in polyclonal infections. EBioMedicine, 2020, 55, 102757.	2.7	41
25	A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria. PLoS Genetics, 2020, 16, e1008576.	1.5	24
26	An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	14
27	Genetic diversity of the Plasmodium falciparum GTP-cyclohydrolase 1, dihydrofolate reductase and dihydropteroate synthetase genes reveals new insights into sulfadoxine-pyrimethamine antimalarial drug resistance. PLoS Genetics, 2020, 16, e1009268.	1.5	15
28	Emergence of Undetectable Malaria Parasites: A Threat under the Radar amid the COVID-19 Pandemic?. American Journal of Tropical Medicine and Hygiene, 2020, 103, 558-560.	0.6	10
29	Genetic dissociation of three antigenic genes in Plasmodium ovale curtisi and Plasmodium ovale wallikeri. PLoS ONE, 2019, 14, e0217795.	1.1	7
30	An analysis of large structural variation in global Plasmodium falciparum isolates identifies a novel duplication of the chloroquine resistance associated gene. Scientific Reports, 2019, 9, 8287.	1.6	8
31	Mosquito and human hepatocyte infections with Plasmodium ovale curtisi and Plasmodium ovale wallikeri. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 617-622.	0.7	3
32	Artemisinin resistance-associated markers in Plasmodium falciparum parasites from the China-Myanmar border: predicted structural stability of K13 propeller variants detected in a low-prevalence area. PLoS ONE, 2019, 14, e0213686.	1.1	18
33	Plasmodium knowlesi exhibits distinct in vitro drug susceptibility profiles from those of Plasmodium falciparum. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 93-99.	1.4	25
34	A New Window on Plasmodium malariae Infections. Journal of Infectious Diseases, 2019, 221, 864-866.	1.9	1
35	Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial. PLoS Medicine, 2019, 16, e1002762.	3.9	33
36	Imported malaria: key messages in an era of elimination. Clinical Medicine, 2019, 19, 153-156.	0.8	2

#	Article	IF	Citations
37	Molecular quantification of Plasmodium parasite density from the blood retained in used RDTs. Scientific Reports, 2019, 9, 5107.	1.6	15
38	Immune Responses to the Sexual Stages of Plasmodium falciparum Parasites. Frontiers in Immunology, 2019, 10, 136.	2.2	17
39	Modification of pfap2Î¼ and pfubp1 Markedly Reduces Ring-Stage Susceptibility of Plasmodium falciparum to Artemisinin In Vitro. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	45
40	No Evidence of Plasmodium falciparum k13 Artemisinin Resistance-Conferring Mutations over a 24-Year Analysis in Coastal Kenya but a Near Complete Reversion to Chloroquine-Sensitive Parasites. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	26
41	Transient temperature fluctuations severely decrease P. falciparum susceptibility to artemisinin in vitro. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 23-26.	1.4	14
42	Rapid and iterative genome editing in the malaria parasite Plasmodium knowlesi provides new tools for P. vivax research. ELife, 2019, 8, .	2.8	61
43	Plasmodium -associated changes in human odor attract mosquitoes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4209-E4218.	3.3	105
44	Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity. Nature Communications, 2018, 9, 558.	5.8	83
45	A reference genome and methylome for the Plasmodium knowlesi A1-H.1 line. International Journal for Parasitology, 2018, 48, 191-196.	1.3	20
46	Pyronaridineâ€“artesunate or dihydroartemisininâ€“piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet, The, 2018, 391, 1378-1390.	6.3	93
47	Geographical and temporal trends and seasonal relapse in Plasmodium ovale spp. and Plasmodium malariae infections imported to the UK between 1987 and 2015. BMC Medicine, 2018, 16, 218.	2.3	18
48	Alternative pathway to reduced artemisinin susceptibility in Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12556-12558.	3.3	9
49	Global genetic diversity of var2csa in Plasmodium falciparum with implications for malaria in pregnancy and vaccine development. Scientific Reports, 2018, 8, 15429.	1.6	35
50	Identifying Recrudescent Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity. Scientific Reports, 2018, 8, 10097.	1.6	14
51	Global analysis of Plasmodium falciparum histidine-rich protein-2 (pfhrp2) and pfhrp3 gene deletions using whole-genome sequencing data and meta-analysis. Infection, Genetics and Evolution, 2018, 62, 211-219.	1.0	40
52	Low Levels of Human Antibodies to Gametocyte-Infected Erythrocytes Contrasts the PfEMP1-Dominant Response to Asexual Stages in P. falciparum Malaria. Frontiers in Immunology, 2018, 9, 3126.	2.2	14
53	Gametocyte Development and Carriage in Ghanaian Individuals with Uncomplicated Plasmodium falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2018, 99, 57-64.	0.6	7
54	Rescuing artemisinin combination therapy in Africa. The Lancet Global Health, 2017, 5, e8-e9.	2.9	4

#	Article	IF	Citations
55	pfk13 -Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	91
56	Selective Whole-Genome Amplification Is a Robust Method That Enables Scalable Whole-Genome Sequencing of Plasmodium vivax from Unprocessed Clinical Samples. MBio, 2017, 8, .	1.8	59
57	Reply to Plucinski et al., â€œInterpreting Data from Passive Surveillance of Antimalarial Treatment Failuresâ€• Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	0
58	Genetic diversity of next generation antimalarial targets: A baseline for drug resistance surveillance programmes. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 174-180.	1.4	12
59	Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents. Journal of Antimicrobial Chemotherapy, 2017, 72, 3051-3058.	1.3	32
60	Contribution of Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera, Indonesia. Journal of Infectious Diseases, 2017, 215, 1148-1155.	1.9	84
61	Plasmodium falciparum parasites with histidine-rich protein 2 (pfhrp2) and pfhrp3 gene deletions in two endemic regions of Kenya. Scientific Reports, 2017, 7, 14718.	1.6	85
62	Reply to van der Pluijm et al., â€œAntimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failuresâ€• Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	0
63	Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence. BMJ Global Health, 2017, 2, e000371.	2.0	23
64	Genetic markers of artemisinin resistance in Plasmodium spp. parasites. Emerging Topics in Life Sciences, 2017, 1, 525-531.	1.1	5
65	Analysis of nuclear and organellar genomes of Plasmodium knowlesi in humans reveals ancient population structure and recent recombination among host-specific subpopulations. PLoS Genetics, 2017, 13, e1007008.	1.5	18
66	Malaria epidemiology in central Myanmar: identification of a multi-species asymptomatic reservoir of infection. Malaria Journal, 2017, 16, 16.	0.8	48
67	Genomic variation in Plasmodium vivax malaria reveals regions under selective pressure. PLoS ONE, 2017, 12, e0177134.	1.1	29
68	Variability of Cutaneous Leishmaniasis Lesions Is Not Associated with Genetic Diversity of Leishmania tropica in Khyber Pakhtunkhwa Province of Pakistan. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1489-1497.	0.6	4
69	Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. PLoS Medicine, 2016, 13, e1002175.	3.9	112
70	Sensitive Detection of Plasmodium vivax Using a High-Throughput, Colourimetric Loop Mediated Isothermal Amplification (HtLAMP) Platform: A Potential Novel Tool for Malaria Elimination. PLoS Neglected Tropical Diseases, 2016, 10, e0004443.	1.3	38
71	Assessment of Markers of Antimalarial Drug Resistance in Plasmodium falciparum Isolates from Pregnant Women in Lagos, Nigeria. PLoS ONE, 2016, 11, e0146908.	1.1	24
72	Phylogenetic position of Leishmania isolates from Khyber Pakhtunkhwa province of Pakistan. Experimental Parasitology, 2016, 167, 61-66.	0.5	5

#	Article	IF	Citations
73	Cutaneous Leishmaniasis in Khyber Pakhtunkhwa Province of Pakistan: Clinical Diversity and Species-Level Diagnosis. American Journal of Tropical Medicine and Hygiene, 2016, 95, 1106-1114.	0.6	45
74	Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V. International Journal for Parasitology: Drugs and Drug Resistance, 2016, 6, 220-229.	1.4	54
75	Persistent Parasitism: The Adaptive Biology of Malariae and Ovale Malaria. Trends in Parasitology, 2016, 32, 808-819.	1.5	67
76	Antibody responses to surface antigens of Plasmodium falciparum gametocyteâ€infected erythrocytes and their relation to gametocytaemia. Parasite Immunology, 2016, 38, 352-364.	0.7	24
77	Paperâ€Origamiâ€Based Multiplexed Malaria Diagnostics from Whole Blood. Angewandte Chemie - International Edition, 2016, 55, 15250-15253.	7.2	125
78	Paperâ€Origamiâ€Based Multiplexed Malaria Diagnostics from Whole Blood. Angewandte Chemie, 2016, 128, 15476-15479.	1.6	29
79	Genome-scale comparison of expanded gene families in Plasmodium ovale wallikeri and Plasmodium ovale curtisi with Plasmodium malariae and with other Plasmodium species. International Journal for Parasitology, 2016, 46, 685-696.	1.3	59
80	Characterizing the impact of sustained sulfadoxine/pyrimethamine use upon the Plasmodium falciparum population in Malawi. Malaria Journal, 2016, 15, 575.	0.8	34
81	A Worldwide Map ofPlasmodium falciparumK13-Propeller Polymorphisms. New England Journal of Medicine, 2016, 374, 2453-2464.	13.9	449
82	Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malaria Journal, 2016, 15, 36.	0.8	54
83	Persistence of chloroquine-resistant haplotypes of Plasmodium falciparum in children with uncomplicated Malaria in Lagos, Nigeria, four years after change of chloroquine as first-line antimalarial medicine. Diagnostic Pathology, 2015, 10, 41.	0.9	26
84	Submicroscopic carriage of Plasmodium falciparum and Plasmodium vivax in a low endemic area in Ethiopia where no parasitaemia was detected by microscopy or rapid diagnostic test. Malaria Journal, 2015, 14, 303.	0.8	56
85	In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs. Experimental Parasitology, 2015, 154, 93-97.	0.5	10
86	Malaria resistance to non-artemisinin partner drugs: how to reACT. Lancet Infectious Diseases, The, 2015, 15, 621-623.	4.6	16
87	The Mu Subunit of Plasmodium falciparum Clathrin-Associated Adaptor Protein 2 Modulates In Vitro Parasite Response to Artemisinin and Quinine. Antimicrobial Agents and Chemotherapy, 2015, 59, 2540-2547.	1.4	42
88	Dimorphism in genes encoding sexual-stage proteins of Plasmodium ovale curtisi and Plasmodium ovale wallikeri. International Journal for Parasitology, 2015, 45, 449-454.	1.3	9
89	Identification and Deconvolution of Cross-Resistance Signals from Antimalarial Compounds Using Multidrug-Resistant Plasmodium falciparum Strains. Antimicrobial Agents and Chemotherapy, 2015, 59, 1110-1118.	1.4	34
90	Alternatively spliced transcripts and novel pseudogenes of the Plasmodium falciparum resistance-associated locus pfcrt detected in East African malaria patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 116-123.	1.3	14

#	Article	IF	Citations
91	A simple, high-throughput, colourimetric, field applicable loop-mediated isothermal amplification (HtLAMP) assay for malaria elimination. Malaria Journal, 2015, 14, 335.	0.8	33
92	Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents and Chemotherapy, 2015, 59, 4387-4396.	1.4	58
93	Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb. PLoS Neglected Tropical Diseases, 2015, 9, e0004068.	1.3	19
94	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal of Tropical Medicine and Hygiene, 2014, 91, 833-843.	0.6	204
95	Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 152-163.	1.4	34
96	Directional Selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu Loci of Plasmodium falciparum in Kenyan Children Treated With ACT. Journal of Infectious Diseases, 2014, 210, 2001-2008.	1.9	108
97	PlasmoView: A Web-based Resource to Visualise Global Plasmodium falciparum Genomic Variation. Journal of Infectious Diseases, 2014, 209, 1808-1815.	1.9	23
98	Changes in Malaria Parasite Drug Resistance in an Endemic Population Over a 25-Year Period With Resulting Genomic Evidence of Selection. Journal of Infectious Diseases, 2014, 209, 1126-1135.	1.9	49
99	estMOI: estimating multiplicity of infection using parasite deep sequencing data. Bioinformatics, 2014, 30, 1292-1294.	1.8	76
100	Hot spot or not: a comparison of spatial statistical methods to predict prospective malaria infections. Malaria Journal, 2014, 13, 53.	0.8	52
101	A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nature Communications, 2014, 5, 4052.	5.8	130
102	African origin of the malaria parasite Plasmodium vivax. Nature Communications, 2014, 5, 3346.	5.8	167
103	Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment. Parasitology, 2014, 141, 1880-1890.	0.7	54
104	A Poisson hierarchical modelling approach to detecting copy number variation in sequence coverage data. BMC Genomics, 2013, 14, 128.	1.2	19
105	Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan. Malaria Journal, 2013, 12, 255.	0.8	21
106	Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal. Malaria Journal, 2013, 12, 137.	0.8	15
107	Gametocyte carriage in Plasmodium falciparum-infected travellers. Malaria Journal, 2013, 12, 31.	0.8	10
108	Combined DNA extraction and antibody elution from filter papers for the assessment of malaria transmission intensity in epidemiological studies. Malaria Journal, 2013, 12, 272.	0.8	55

#	Article	IF	Citations
109	Persistent detection of Plasmodium falciparum, P. malariae, P. ovale curtisi and P. ovale wallikeri after ACT treatment of asymptomatic Ghanaian school-children. International Journal for Parasitology: Drugs and Drug Resistance, 2013, 3, 45-50.	1.4	89
110	Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. Malaria Journal, 2013, 12, 320.	0.8	36
111	An Augmented Reality Haptic Training Simulator for Spinal Needle Procedures. IEEE Transactions on Biomedical Engineering, 2013, 60, 3009-3018.	2.5	74
112	Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malaria Journal, 2013, 12, 221.	0.8	95
113	Highly Sensitive Detection of Malaria Parasitemia in a Malaria-Endemic Setting: Performance of a New Loop-Mediated Isothermal Amplification Kit in a Remote Clinic in Uganda. Journal of Infectious Diseases, 2013, 208, 645-652.	1.9	241
114	Clinical Evaluation of a Loop-Mediated Amplification Kit for Diagnosis of Imported Malaria. Journal of Infectious Diseases, 2013, 208, 637-644.	1.9	134
115	Genetic Marker Suitable for Identification and Genotyping of Plasmodium ovale curtisi and Plasmodium ovale wallikeri. Journal of Clinical Microbiology, 2013, 51, 4213-4216.	1.8	20
116	Residual Plasmodium falciparum Parasitemia in Kenyan Children After Artemisinin-Combination Therapy Is Associated With Increased Transmission to Mosquitoes and Parasite Recurrence. Journal of Infectious Diseases, 2013, 208, 2017-2024.	1.9	109
117	The Polymorphic Linker Domain ofpfmdr1Is Associated with Resistance-Conferring Mutations in Plasmodium falciparum Populations from East and West Africa. Antimicrobial Agents and Chemotherapy, 2013, 57, 4595-4598.	1.4	3
118	Malaria Transmission After Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine: A Randomized Trial. Journal of Infectious Diseases, 2013, 207, 1637-1645.	1.9	99
119	HIV-Positive Nigerian Adults Harbor Significantly Higher Serum Lumefantrine Levels than HIV-Negative Individuals Seven Days after Treatment for Plasmodium falciparum Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 4146-4150.	1.4	10
120	Inactivation of <scp>P</scp>lasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion, 2013, 53, 3174-3183.	0.8	31
121	Repeat Polymorphisms in the Low-Complexity Regions of Plasmodium falciparum ABC Transporters and Associations with In Vitro Antimalarial Responses. Antimicrobial Agents and Chemotherapy, 2013, 57, 6196-6204.	1.4	16
122	An observational study of malaria in British travellers:Plasmodium ovale wallikeriandPlasmodium ovale curtisidiffer significantly in the duration of latency. BMJ Open, 2013, 3, e002711.	0.8	69
123	Diversity of T Cell Epitopes in Plasmodium falciparum Circumsporozoite Protein Likely Due to Protein-Protein Interactions. PLoS ONE, 2013, 8, e62427.	1.1	22
124	Various pfcrt and pfmdr1 Genotypes of Plasmodium falciparum Cocirculate with P. malariae, P. ovale spp., and P. vivax in Northern Angola. Antimicrobial Agents and Chemotherapy, 2012, 56, 5271-5277.	1.4	51
125	Expression of a type B RIFIN in Plasmodium falciparum merozoites and gametes. Malaria Journal, 2012, 11, 429.	0.8	23
126	Filter paper collection of Plasmodium falciparum mRNA for detecting low-density gametocytes. Malaria Journal, 2012, 11, 266.	0.8	33

#	Article	IF	Citations
127	Recognition of Plasmodium falciparum gametocyte surface antigens by plasma antibodies in asymptomatic Ghanaian school children. Malaria Journal, 2012, 11, .	0.8	1
128	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature, 2012, 487, 375-379.	13.7	450
129	Increased sensitivity for detecting malaria parasites in human umbilical cord blood using scaled-up DNA preparation. Malaria Journal, 2012, 11, 62.	0.8	10
130	Mosquito Feeding Assays to Determine the Infectiousness of Naturally Infected Plasmodium falciparum Gametocyte Carriers. PLoS ONE, 2012, 7, e42821.	1.1	168
131	Genomic Insights into the Past, Current and Future Evolution of Human Parasites of the Genus Plasmodium. , 2011, , 607-635.		5
132	Drug-Resistant Genotypes and Multi-Clonality in Plasmodium falciparum Analysed by Direct Genome Sequencing from Peripheral Blood of Malaria Patients. PLoS ONE, 2011, 6, e23204.	1.1	41
133	Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?. Parasitology, 2011, 138, 1459-1468.	0.7	13
134	Human immune responses that reduce the transmission of Plasmodium falciparum in African populations. International Journal for Parasitology, 2011, 41, 293-300.	1.3	56
135	Plasmodium ovale curtisi and Plasmodium ovale wallikeri circulate simultaneously in African communities. International Journal for Parasitology, 2011, 41, 677-683.	1.3	125
136	Towards an augmented ultrasound guided spinal needle insertion system. , 2011, 2011, 3459-62.		2
137	Increased pfmdr1 Copy Number and Sequence Polymorphisms in Plasmodium falciparum Isolates from Sudanese Malaria Patients Treated with Artemether-Lumefantrine. Antimicrobial Agents and Chemotherapy, 2011, 55, 5408-5411.	1.4	61
138	The perils of PCR: can we accurately â€˜correctâ€™ antimalarial trials?. Trends in Parasitology, 2010, 26, 119-124.	1.5	45
139	Assessing agreement between malaria slide density readings. Malaria Journal, 2010, 9, 4.	0.8	21
140	Dynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum. Malaria Journal, 2010, 9, 74.	0.8	29
141	Promiscuous Expression of Î±-Tubulin II in Maturing Male and Female Plasmodium falciparum Gametocytes. PLoS ONE, 2010, 5, e14470.	1.1	27
142	Mitochondrial DNA Targets Increase Sensitivity of Malaria Detection Using Loop-Mediated Isothermal Amplification. Journal of Clinical Microbiology, 2010, 48, 2866-2871.	1.8	147
143	Amodiaquine Resistance in Plasmodium falciparum Malaria in Afghanistan Is Associated with the pfcrt SVMNT Allele at Codons 72 to 76. Antimicrobial Agents and Chemotherapy, 2010, 54, 3714-3716.	1.4	72
144	Two Nonrecombining Sympatric Forms of the Human Malaria ParasitePlasmodium ovaleOccur Globally. Journal of Infectious Diseases, 2010, 201, 1544-1550.	1.9	310

#	Article	IF	Citations
145	Measuring the efficacy of anti-malarial drugs in vivo: quantitative PCR measurement of parasite clearance. Malaria Journal, 2010, 9, 312.	0.8	61
146	Identification of a major rif transcript common to gametocytes and sporozoites of Plasmodium falciparum. Malaria Journal, 2010, 9, 147.	0.8	28
147	Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malaria Journal, 2010, 9, 136.	0.8	223
148	Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates. Malaria Journal, 2010, 9, 68.	0.8	38
149	Loss of Population Levels of Immunity to Malaria as a Result of Exposure-Reducing Interventions: Consequences for Interpretation of Disease Trends. PLoS ONE, 2009, 4, e4383.	1.1	86
150	Novel pfdhps Haplotypes among Imported Cases of Plasmodium falciparum Malaria in the United Kingdom. Antimicrobial Agents and Chemotherapy, 2009, 53, 3405-3410.	1.4	50
151	Detecting Malaria Parasites outside the Blood. Journal of Infectious Diseases, 2009, 199, 1561-1563.	1.9	25
152	Surface antigens of Plasmodium falciparum gametocytesâ€"A new class of transmission-blocking vaccine targets?. Molecular and Biochemical Parasitology, 2009, 166, 93-98.	0.5	55
153	Submicroscopic Gametocytes and the Transmission of Antifolate-Resistant Plasmodium falciparum in Western Kenya. PLoS ONE, 2009, 4, e4364.	1.1	20
154	Impact of RTS,S/AS02A and RTS,S/AS01B on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial. PLoS ONE, 2009, 4, e7849.	1.1	50
155	Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malaria Journal, 2008, 7, 249.	0.8	74
156	Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Malaria Journal, 2008, 7, 240.	0.8	57
157	Establishment of the 1st World Health Organization International Standard for Plasmodium falciparum DNA for nucleic acid amplification technique (NAT)-based assays. Malaria Journal, 2008, 7, 139.	0.8	60
158	Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malaria Journal, 2008, 7, 125.	0.8	139
159	Cluster of Falciparum Malaria Cases in UK Airport. Emerging Infectious Diseases, 2008, 14, 1284-1286.	2.0	13
160	Human Infections withPlasmodium knowlesi,the Philippines. Emerging Infectious Diseases, 2008, 14, 811-813.	2.0	178
161	Comparing Highly Efficacious Antimalarial Drugs. PLoS Medicine, 2008, 5, e228.	3.9	7
162	A Trial of the Efficacy, Safety and Impact on Drug Resistance of Four Drug Regimens for Seasonal Intermittent Preventive Treatment for Malaria in Senegalese Children. PLoS ONE, 2008, 3, e1471.	1.1	83

#	Article	IF	Citations
163	Plasmodium falciparum Antigens on the Surface of the Gametocyte-Infected Erythrocyte. PLoS ONE, 2008, 3, e2280.	1.1	70
164	ama1 Genes of Sympatric Plasmodium vivax and P. falciparum from Venezuela Differ Significantly in Genetic Diversity and Recombination Frequency. PLoS ONE, 2008, 3, e3366.	1.1	51
165	Determination of the Processes Driving the Acquisition of Immunity to Malaria Using a Mathematical Transmission Model. PLoS Computational Biology, 2007, 3, e255.	1.5	155
166	A Challenge for the Development of Malaria Vaccines: Polymorphic Target Antigens. PLoS Medicine, 2007, 4, e116.	3.9	14
167	Chloroquine-resistant Plasmodium falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis. Journal of Antimicrobial Chemotherapy, 2007, 59, 1197-1199.	1.3	43
168	Seasonal Carriage ofpfcrtandpfmdr1Alleles in GambianPlasmodium falciparumImply Reduced Fitness of Chloroquineâ€Resistant Parasites. Journal of Infectious Diseases, 2007, 196, 1613-1619.	1.9	82
169	Children in Burkina Faso Who Are Protected by Insecticideâ€Treated Materials Are Able to Clear Drugâ€Resistant Parasites Better than Unprotected Children. Journal of Infectious Diseases, 2007, 196, 138-144.	1.9	12
170	How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions?. Malaria Journal, 2007, 6, 161.	0.8	39
171	World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria. Malaria Journal, 2007, 6, 121.	0.8	99
172	Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malaria Journal, 2007, 6, 9.	0.8	29
173	Plasmodium malariaein Haitian Refugees, Jamaica. Emerging Infectious Diseases, 2007, 13, 931-933.	2.0	26
174	Differential evidence of natural selection on two leading sporozoite stage malaria vaccine candidate antigens. International Journal for Parasitology, 2007, 37, 77-85.	1.3	45
175	Response to Duffy and Tham: Transcription and coregulation of multigene families in Plasmodium falciparum. Trends in Parasitology, 2007, 23, 186-187.	1.5	2
176	Improved synchronous production of Plasmodium falciparum gametocytes in vitro. Molecular and Biochemical Parasitology, 2007, 154, 119-123.	0.5	200
177	SUSTAINED USE OF INSECTICIDE-TREATED CURTAINS IS NOT ASSOCIATED WITH GREATER CIRCULATION OF DRUG-RESISTANT MALARIA PARASITES, OR WITH HIGHER RISK OF TREATMENT FAILURE AMONG CHILDREN WITH UNCOMPLICATED MALARIA IN BURKINA FASO. American Journal of Tropical Medicine and Hygiene, 2007, 76, 237-244.	0.6	16
178	Sustained use of insecticide-treated curtains is not associated with greater circulation of drug-resistant malaria parasites, or with higher risk of treatment failure among children with uncomplicated malaria in Burkina Faso. American Journal of Tropical Medicine and Hygiene, 2007, 76, 237-44.	0.6	9
179	Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet, The, 2006, 367, 659-667.	6.3	181
180	The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends in Parasitology, 2006, 22, 424-430.	1.5	166

#	Article	IF	Citations
181	Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum. PLOS Clinical Trials, 2006, 1, e14.	3.5	34
182	RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection. PLOS Clinical Trials, 2006, 1, e5.	3.5	70
183	Chloroquine/Sulphadoxine-Pyrimethamine for Gambian Children with Malaria: Transmission to Mosquitoes of Multidrug-Resistant Plasmodium falciparum. PLOS Clinical Trials, 2006, 1, e15.	3.5	71
184	Programmed Transcription of the var Gene Family, but Not of stevor , in Plasmodium falciparum Gametocytes. Eukaryotic Cell, 2006, 5, 1206-1214.	3.4	63
185	Moderate Effect of Artemisininâ€Based Combination Therapy on Transmission ofPlasmodium falciparum. Journal of Infectious Diseases, 2006, 193, 1151-1159.	1.9	183
186	Immunoglobulin G Antibodies to Merozoite Surface Antigens Are Associated with Recovery from Chloroquine-Resistant Plasmodium falciparum in Gambian Children. Infection and Immunity, 2006, 74, 2887-2893.	1.0	14
187	Gametocytaemia after Drug Treatment of Asymptomatic Plasmodium falciparum. PLOS Clinical Trials, 2006, 1, e20.	3.5	77
188	High sequence diversity and evidence of balancing selection in the Pvmsp3Î± gene of Plasmodium vivax in the Venezuelan Amazon. Molecular and Biochemical Parasitology, 2005, 144, 86-93.	0.5	39
189	Reduction of Malaria Transmission to Anopheles Mosquitoes with a Six-Dose Regimen of Co-Artemether. PLoS Medicine, 2005, 2, e92.	3.9	159
190	Carriage of Chloroquineâ€Resistant Parasites and Delay of Effective Treatment Increase the Risk of Severe Malaria in Gambian Children. Journal of Infectious Diseases, 2005, 192, 1651-1657.	1.9	44
191	Combination Therapy Counteracts the Enhanced Transmission of Drug-Resistant Malaria Parasites to Mosquitoes. Antimicrobial Agents and Chemotherapy, 2004, 48, 3940-3943.	1.4	70
192	Plasmodium falciparum Associated with Severe Childhood Malaria Preferentially Expresses PfEMP1 Encoded by Group A var Genes. Journal of Experimental Medicine, 2004, 199, 1179-1190.	4.2	292
193	Distinct Trafficking and Localization of STEVOR Proteins in Three Stages of the Plasmodium falciparum Life Cycle. Infection and Immunity, 2004, 72, 6597-6602.	1.0	76
194	Vaccination for vivax malaria: targeting the invaders. Trends in Parasitology, 2004, 20, 99-102.	1.5	19
195	Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Tropical Medicine and International Health, 2004, 9, 53-61.	1.0	72
196	Sympatric Plasmodium falciparum isolates from Venezuela have structured var gene repertoires. Malaria Journal, 2003, 2, 7.	0.8	28
197	THE ADDITION OF ARTESUNATE TO CHLOROQUINE FOR TREATMENT OF PLASMODIUM FALCIPARUM MALARIA IN GAMBIAN CHILDREN DELAYS, BUT DOES NOT PREVENT TREATMENT FAILURE. American Journal of Tropical Medicine and Hygiene, 2003, 69, 19-25.	0.6	24
198	The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children delays, but does not prevent treatment failure. American Journal of Tropical Medicine and Hygiene, 2003, 69, 19-25.	0.6	18

#	Article	IF	Citations
199	Genetic complexity of Plasmodium falciparum gametocytes isolated from the peripheral blood of treated Gambian children.. American Journal of Tropical Medicine and Hygiene, 2002, 66, 700-705.	0.6	16
200	Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes.. American Journal of Tropical Medicine and Hygiene, 2002, 67, 578-585.	0.6	94
201	Stevor transcripts from Plasmodium falciparum gametocytes encode truncated polypeptides. Molecular and Biochemical Parasitology, 2001, 113, 331-335.	0.5	24
202	Artesunate Reduces but Does Not Prevent Posttreatment Transmission ofPlasmodium falciparumtoAnopheles gambiae. Journal of Infectious Diseases, 2001, 183, 1254-1259.	1.9	210
203	A Model for Sequestration of the Transmission Stages of Plasmodium falciparum : Adhesion of Gametocyte-Infected Erythrocytes to Human Bone Marrow Cells. Infection and Immunity, 2000, 68, 3455-3462.	1.0	89
204	The cytoadherence linked asexual gene family of Plasmodium falciparum : are there roles other than cytoadherence? 1Note: Nucleotide sequence data reported in this paper are available in the GenBank data base under the accession numbers AF055476, AE001362 and Z97348 and at the databases of the Sanger Centre (http://www.sanger.ac.uk/Projects/P_falciparum) and the Institute for Genomic Reaseach (http://www.tigr.org/tdb/mdb/pfdb). 1. International Journal for Parasitology, 1999, 29, 939-944.	1.3	50
205	Disruption of a novel open reading frame of Plasmodium falciparum chromosome 9 by subtelomeric and internal deletions can lead to loss or maintenance of cytoadherence. Molecular and Biochemical Parasitology, 1996, 82, 25-36.	0.5	31
206	Identification of a program of contractile protein gene expression initiated upon skeletal muscle differentiation. Developmental Dynamics, 1993, 196, 25-36.	0.8	55
207	Coordination of skeletal muscle gene expression occurs late in mammalian development. Developmental Biology, 1991, 146, 167-178.	0.9	51
208	Regulation of contractile protein gene family mRNA pool sizes during myogenesis. Developmental Biology, 1990, 142, 270-282.	0.9	37